Statistics from Altmetric.com
Rituximab is a chimeric antibody against CD20 aimed at depleting B cells. While originally developed as a treatment for B cell lymphomas, it was recently found to be useful in managing autoimmune diseases including refractory Wegener’s granulomatosis.1–3 We report a case of refractory peripheral ulcerative keratitis (PUK) associated with Wegener’s granulomatosis that was successfully treated with rituximab.
A 57 year old man with longstanding Wegener’s granulomatosis was admitted to the hospital with severe pain and blurred vision in the left eye as well as respiratory compromise because of tracheal …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.